April 28, 2008 - Osteotech Inc. said the FDA cleared its Plexur P Biocomposite for use in spinal applications as a bone void filler and as a bone graft extender.
Previously, Osteotech received FDA clearance for Plexur P for use in filling bony voids of the pelvis and extremities.
According to Osteotech, the Plexur P Biocomposite has been used by a variety of surgeons in tibial plateau fractures, tibial osteotomies and a variety of foot and ankle procedures, and can now be used in the spine. The Plexur P can be combined with the company�s Grafton DBM, local bone or the Kinesis BMAC cellular system. Plexur P is available as granules, cylinders, blocks, wedges and sheets. The Plexur uses bone tissue for procedure specific surgical applications in combination with a wide variety of polymers.
For more information: www.osteotech.com
October 30, 2026 
